JP2025509730A - 循環タンパク質の選択的分解を目的とした二官能性小分子 - Google Patents

循環タンパク質の選択的分解を目的とした二官能性小分子 Download PDF

Info

Publication number
JP2025509730A
JP2025509730A JP2024555107A JP2024555107A JP2025509730A JP 2025509730 A JP2025509730 A JP 2025509730A JP 2024555107 A JP2024555107 A JP 2024555107A JP 2024555107 A JP2024555107 A JP 2024555107A JP 2025509730 A JP2025509730 A JP 2025509730A
Authority
JP
Japan
Prior art keywords
alkyl
compound
disease
group
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509730A5 (https=
JPWO2023178202A5 (https=
Inventor
デイビッド スピーゲル
デイビッド カイアニエッロ
メンウェン チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/695,645 external-priority patent/US12485178B2/en
Application filed by Yale University filed Critical Yale University
Publication of JP2025509730A publication Critical patent/JP2025509730A/ja
Publication of JP2025509730A5 publication Critical patent/JP2025509730A5/ja
Publication of JPWO2023178202A5 publication Critical patent/JPWO2023178202A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024555107A 2022-03-15 2023-03-15 循環タンパク質の選択的分解を目的とした二官能性小分子 Pending JP2025509730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/695,645 2022-03-15
US17/695,645 US12485178B2 (en) 2018-04-09 2022-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins
PCT/US2023/064470 WO2023178202A2 (en) 2022-03-15 2023-03-15 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (3)

Publication Number Publication Date
JP2025509730A true JP2025509730A (ja) 2025-04-11
JP2025509730A5 JP2025509730A5 (https=) 2026-03-24
JPWO2023178202A5 JPWO2023178202A5 (https=) 2026-03-24

Family

ID=88024440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555107A Pending JP2025509730A (ja) 2022-03-15 2023-03-15 循環タンパク質の選択的分解を目的とした二官能性小分子

Country Status (8)

Country Link
EP (1) EP4493222A2 (https=)
JP (1) JP2025509730A (https=)
KR (1) KR20240166514A (https=)
CN (1) CN119255822A (https=)
AU (1) AU2023236291A1 (https=)
IL (1) IL315579A (https=)
MX (1) MX2024011338A (https=)
WO (1) WO2023178202A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022310356A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
US12364766B2 (en) * 2018-04-09 2025-07-22 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199621A1 (en) * 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
CN113301925A (zh) * 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 用于溶酶体靶向的双官能分子以及相关的组合物和方法
IL294515A (en) * 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins

Also Published As

Publication number Publication date
EP4493222A2 (en) 2025-01-22
MX2024011338A (es) 2024-12-06
AU2023236291A1 (en) 2024-10-03
CN119255822A (zh) 2025-01-03
WO2023178202A2 (en) 2023-09-21
IL315579A (en) 2024-11-01
WO2023178202A3 (en) 2023-10-26
KR20240166514A (ko) 2024-11-26

Similar Documents

Publication Publication Date Title
US20250332274A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
US20240083859A1 (en) Bi-functional Molecules To Degrade Circulating Proteins
JP2025509730A (ja) 循環タンパク質の選択的分解を目的とした二官能性小分子
CN105407920B (zh) 靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
CA3226492A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
US12485178B2 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
US12083181B2 (en) Bi-functional molecules to degrade circulating proteins
KR20250172727A (ko) 순환성 단백질의 선택적 분해를 표적화하는 이중기능성 소분자
CN117069793A (zh) 双功能接头化合物、抗体药物偶联物及其制备方法和应用
WO2025149012A1 (zh) Dolastatin衍生物及其制备方法和应用
JP2025509736A (ja) 循環タンパク質を分解するための二官能性分子
HK40042237A (en) Bifunctional small molecules to target the selective degradation of circulating proteins
JP2026508972A (ja) 関節炎の処置、寛解、または防止のための化合物および方法
HK1222564B (zh) 靶向癌症、尤其是前列腺癌的合成性抗體模擬化合物(syams)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313